Lansoprazole Tablet, Orally Disintegrating, Delayed Release
Product Images NDC 55154-4848

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 55154-4848). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (C9a43df0 Efab 4486 860f 92afdb258c8b 00)

Bag Label (C9a43df0 Efab 4486 860f 92afdb258c8b 00)
This is a medication containing lansoprazole in a delayed-release orally disintegrating tablet form in a package of 10 tablets. Each tablet contains 30 mg of lansoprazole, USP as enteric-coated microgranules. It is stored at a temperature of 20° to 25° C. The package is not child-resistant and is designated for institutional use only. The medication guide should be dispensed to each patient, and the medication must be stored out of children's reach. It is manufactured in Israel by Teva Pharmaceutical Industries Ltd for Teva Pharmaceuticals USA, Inc. and distributed by Cardinal Health. The product insert should be consulted for complete prescribing information, precautions, and warnings. The text contains standard pharmaceutical warning and storage information.*
FDA Label Image

Chemical Structure (Image 1)

Chemical Structure (Image 1)
FDA Label Image

Figure-01 (Image 2)

Figure-01 (Image 2)
FDA Label Image

Figure-02 (Image 3)

Figure-02 (Image 3)
This is a graph showing the average severity of night heartburn for patients in a study. The severity is ranked on a scale of 0 to 3: 0 indicating no heartburn and 3 indicating severe heartburn. The study includes patients receiving a placebo and patients receiving different doses of Lansoprazole (a medication used to treat heartburn and acid reflux). The graph shows the severity of heartburn over a period of 56 days from the start of treatment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.